Editorial
New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019

https://doi.org/10.1016/j.jtho.2022.03.001Get rights and content
Under an Elsevier user license
open archive

Cited by (0)

Disclosures: Dr. Zhong reports receiving speech honoraria from AstraZeneca, Roche, Eli Lilly, and Pfizer. Dr. Wu reports receiving research funding from Roche; receiving speech honoraria from AstraZeneca, Roche, Eli Lilly, Pfizer, and Sanofi; and serving as a research consultant for AstraZeneca. Dr. Zhang declares no conflict of interest.

© 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc.